Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers

Journal of Surgical Oncology

Volumn 96, Issue 3, 2007, Pages 220-229

  Makari, Yoichi ^a   Yasuda, Takushi ^a   Doki, Yuichiro ^a,b   Miyata, Hiroshi ^a   Fujiwara, Yoshiyuki ^a   Takiguchi, Shuji ^a   Matsuyama, Jin ^a   Yamasaki, Makoto ^a   Hirao, Takafumi ^c   Koyama, Mitsuhiro ^a   Nakamuara, Hironobu ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NONE

Author keywords

Angiogenesis; Chemoradiotherapy; Chemotherapy; CT perfusion; Esophageal cancer; Neoadjuvant therapy

Indexed keywords

CISPLATIN; CONTRAST MEDIUM; DOXORUBICIN; FLUOROURACIL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; SQUAMOUS CELL CARCINOMA; TUMOR BLOOD FLOW; BLOOD FLOW; ESOPHAGUS TUMOR; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; VASCULARIZATION;

AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGIONAL BLOOD FLOW; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35448953999     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20820     Document Type: Article

References (41)

1. Urschel JD, Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-543.
2. Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727-1733.
3. Stahl M, Stuschke M, Lehmann N, et al.: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
4. Kishi K, Doki Y, Miyata H, et al.: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 2002;89:597-603.
5. Miyata H, Doki Y, Shiozaki H, et al.: CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res 2000;6:4859-4865.
6. Takeuchi H, Ozawa S, Ando N, et al.: Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol 2003;10:792-800.
7. Hironaka S, Hasebe T, Kamijo T, et al.: Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 2002;8:124-130.
8. Shimada H, Hoshino T, Okazumi S, et al.: Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86:552-557.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
10. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
11. Burke D, Carnochan P, Glover C, et al.: Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model. Clin Exp Metastasis 2000;18:617-622.
12. Davies MM, Burke D, Carnochan P, et al.: Basic fibroblast growth factor infusion increases tumour vascularity, blood flow and chemotherapy uptake. Acta Oncol 2002;41:84-90.
13. Semenza GL: Targeting, HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
14. Erkan M, Kleeff J, Esposito I, et al.: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005;24:4421-4432.
15. De Milito A, Fais S: Tumor acidity, chemoresistance and proton pump inhibitors. Fut Oncol 2005;1:779-786.
16. Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK: Principles and Practice of Radiation Oncology. 4th edition. editors. New York: Lippincott-Raven Publishers; 2003.
17. Koukourakis MI, Giatromanolaki A, Sivridis E, et al.: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-1202.
18. Hui EP, Chan AT, Pezzella F, et al.: Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-2604.
19. Laking GR, West C, Buckley DL, et al.: Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol 2006;58:95-113.
20. Ng QS, Goh V, Fichte H, et al.: Lung cancer perfusion at multidetector row CT: reproducibility of whole tumor quantitative measurements. Radiology 2006;239:547-553.
21. Klotz E, Konig M: Perfusion measurements of the brain: using dynamic CT for the quantitative assessment of cerebral ischemia in acute stroke. Eur J Radiol 1999;30:170-184.
22. Sahani DV, Kalva SP, Hamberg LM, et al.: Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 2005;234:785-792.
23. Gandhi D, Chepeha DB, Miller T, et al.: Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol 2006;27:101-106.
24. Miles KA: Perfusion, CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003;76(Spec No 1):S36-S42.
25. Sobin LH, Wittekind C: TNM classification of malignant tumours. 6th edition. New York: John Wiley and Sons, Inc; 2002.
26. Akita H, Doki Y, Miyata H, et al.: Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol 2006;93:401-409.
27. Doki Y, Ishikawa O, Mano M, et al.: Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers. J Surg Res 2002;107:75-81.
28. Doki Y, Takachi K, Ishikawa O, et al.: Reduced tumor vessel density and high expression of glucose transporter 1 suggest tumor hypoxia of squamous cell carcinoma of the esophagus surviving after radiotherapy. Surgery 2005;137:536-544.
29. Yano M, Yasuda T, Miyata H, et al.: Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus. J Surg Oncol 2005;89:244-250.
30. Doki Y, Ishikawa O, Takachi K, et al.: Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg 2005;29:700-707.
31. DeVita V, Hellmann S, Rosenberg S: Cancer Princiles and Practice of Oncology. 7th Edition editors. Philadelphia, PA: Lippincott Williams and Wilkins; 2005.
32. Hasan J, Byers R, Jayson GC: Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002;86:1566-1577.
33. Maehara Y, Kabashima A, Koga T, et al.: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 2000;128:408-416.
34. Miles KA, Griffiths MR, Keith CJ: Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:22-28.
35. Li ZP, Meng QF, Sun CH, et al.: Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. World J Gastroenterol 2005;11:1287-1291.
36. Haider MA, Milosevic M, Fyles A, et al.: Assessment of the tumor microenvironment in cervix cancer using dynamic contrast enhanced CT, interstitial fluid pressure and oxygen measurements. Int J Radiat Oncol Biol Phys 2005;62:1100-1107.
37. Garcia-Barros M, Paris F, Cordon-Cardo C, et al.: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-1159.
38. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31-36.
39. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
40. Fleischer AC, Niermann KJ, Donnelly EF, et al.: Sonographic depiction of microvessel perfusion: principles and potential. J Ultrasound Med 2004;23:1499-1506.
41. Shibamoto Y, Sugie C, Ito M, et al.: The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs. Expert Opin Pharmacother 2004;5:2459-2467.